DOV Pharmaceutical
| Company type | Public company (until 2010) |
|---|---|
| Industry | Biotechnology, Pharmaceuticals |
| Founded | 1995 |
| Founder | Former employees of American Cyanamid |
| Defunct | 2010 |
| Fate | Acquired by Euthymics Bioscience |
| Headquarters | United States |
Key people | Phil Skolnick (Chief Scientific Officer, 2001–2009) |
| Products | Indiplon, Bicifadine, Amitifadine (EB-1010), Ocinaplon, Diltiazem formulation, DOV 102,677, DOV 51,892, DOV-216,303 |
DOV Pharmaceutical operated as a biotechnology firm focused on developing treatments for disorders affecting the central nervous system. Established in 1995 by former employees of American Cyanamid, the company obtained licenses for drugs from American Cyanamid in 1998 to further their development.[1] In 2002, DOV went public on the NASDAQ, but its stock value significantly declined following disclosures regarding a previous association with Élan.[2]
Phil Skolnick held the position of Chief Scientific Officer between 2001 and 2009.[3] Euthymics Bioscience, created by Anthony McKinney alongside Frank Bymaster—an ex-Eli Lilly chemist who contributed to the development of Prozac and Cymbalta—raised $24 million from Novartis Venture Funds and additional investors.[4]
Following several unsuccessful clinical trials, DOV was acquired by Euthymics Bioscience in 2010. Euthymics intended to advance the development of DOV’s antidepressant amitifadine (DOV 21,947), which was rebranded as EB-1010.[5]
Prominent drug candidates encompassed:
- Indiplon, targeting insomnia, initially licensed from Wyeth in 1998 and later sublicensed to Neurocrine Biosciences.[1]
- Bicifadine, a triple-uptake inhibitor designed for pain management, licensed from Wyeth.[6]
- Triple-uptake inhibitors aimed at treating depression (DOV 21,947 and DOV 216,303), originally licensed from Wyeth; these were sublicensed to Merck in 2004 but the agreement ended in 2006.[6][7][8]
- Ocinaplon, developed for anxiety-related conditions.[9]
- A unique formulation of diltiazem[9]
- DOV 102,677, intended for Parkinson’s disease, restless leg syndrome, and attention deficit disorder[9]
- DOV 51,892, targeting anxiety disorders[9]
- DOV-216,303, a racemic compound that includes amitifadine; development ceased following patent expiration.[10]
External links
- ↑ 1.0 1.1 Cite error: Invalid
<ref>tag; no text was provided for refs namedNeubauer - ↑ Hess, Diane, Drugmaker's IPO Is a Big Headache, TheStreet.com, 1 May 2002.
- ↑ "Press Release: Dr. Phil Skolnick Now Leads NIDA's Medications Development Efforts". National Institute on Drug Abuse. 1 April 2010.
- ↑ McCoy, Michael (12 March 2012). "Happy Results for a Depression Drug". Chemical & Engineering News Archive. 90 (11): 20–22.
- ↑ Fierce Biotech 22 July 2010 Euthymics lands $24M to fund antidepressant work
- ↑ 6.0 6.1 Cite error: Invalid
<ref>tag; no text was provided for refs namedMarks - ↑ Chemical and Engineering News. 12 August 2004 Merck and DOV Pharmaceutical In Drug Pact
- ↑ Dov 8 December 2006 DOV Announces Termination Of License Agreement With Merck
- ↑ 9.0 9.1 9.2 9.3 Cite error: Invalid
<ref>tag; no text was provided for refs namedEdgarBizDescrip - ↑ "10-K For fiscal year ended December 31, 2007". Dov Pharmaceutical via SEC Edgar. 31 March 2008.
- United States biotechnology firms
- Businesses located in Bergen County, New Jersey
- New Jersey pharmaceutical corporations
- Biotech companies founded in 1995
- 1995 New Jersey establishments
- Biotechnology firms closed in 2010
- 2010 closures in New Jersey
- American corporations founded in 1995
- American companies established in 1995